Categories Health Care

Will Zynerba Zygel trial be extended amid safety warning?

Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock retreated on Wednesday after serious adverse events in phase 2 clinical trial of transdermal cannabidiol gel, Zygel. The shares were weak lately as the stock has fallen over 17% in the past month and over 31% in the past three months. Investors remained concerned about the company’s future and raised doubts about the trial extension due to the adverse events.

The company achieved positive results from the trial evaluating topical gel Zygel in children and adolescents with developmental and epileptic encephalopathies, a group of rare pediatric epilepsy syndromes including Dravet and Lennox-Gastaut. Through six months of therapy, 96% of patients experienced a treatment-emergent adverse event and 60% experienced a treatment-related adverse event.

This raised doubts and widens Zynerba’s hopes of turning profitable by the end of next year. The company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $138.2 million as of June 30, 2019. The company is expected to incur additional losses until significant revenue from its product candidates is achieved. The primary source of liquidity for Zynerba has been the issuance of equity securities.

Image for representation. Courtesy: PublicDomainPictures from Pixabay

The company’s operations and capital requirements are anticipated to be funded by current cash and cash equivalents and the proceeds anticipated from the advance overseas finding until the second half of 2021. Also, Zynerba is likely to go for additional financings for funding its operations and completing clinical development of its product candidates.

Zygel has completed three Phase 2 clinical trials and two of those studies have open-label extensions that are ongoing. For the continuation of the trials, the company required additional funding. However, traders fear that the company raising additional capital could cause dilution to its existing stockholders, restrict operations or require it to relinquish rights to its technologies or product candidates.

Read: General Mills Q1 earnings review

Zygel is a cannabidiol (CBD) permeation-enhanced transdermal gel. The company is focused on developing a transdermally-delivered cannabinoid therapeutics for patients affected by rare and near-rare neuropsychiatric conditions.

The company’s shares have been highly dependent on sentiment across the broader cannabis space. The company’s valuation has turned out to be risky due to extremely volatile stock movements that attract speculators and cannabis enthusiasts blinded by emotion.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

What to look for when CVS Health (CVS) reports Q3 earnings

Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain

eBay (EBAY): A few factors that helped drive growth in Q3 2024

Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,

CVX Earnings: Chevron reports lower revenue and profit for Q3 2024

Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top